ERBB2 and breast cancer: Abemaciclib was recently licensed by the FDA as the first and only CDK4/6 inhibitor for use in HR+/HER2 node-positive early breast cancer patients with a Ki-67 score of less than 20% and a high risk of recurrence [62].